GenFleet Therapeutics (Shanghai) Inc. (HKG:2595)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
42.78
-5.32 (-11.06%)
At close: Apr 28, 2026
Market Cap 17.81B
Revenue (ttm) 144.96M
Net Income (ttm) -2.00B
Shares Out 370.37M
EPS (ttm) -6.75
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,387,546
Average Volume 2,520,765
Open 48.50
Previous Close 48.10
Day's Range 42.38 - 49.56
52-Week Range 19.60 - 52.90
Beta n/a
RSI 54.47
Earnings Date Mar 24, 2026

About HKG:2595

GenFleet Therapeutics (Shanghai) Inc. operates as a biopharmaceutical company that focuses on developing novel treatment options in the fields of oncology that cover different lines of treatments of multiple solid tumors, as well as autoimmune and inflammatory diseases. The company’s products include GFH925, help for the treatment of advanced non-small cell lung cancer, and GFH375, an orally bioavailable small molecule inhibitor of Kirsten rat sarcoma (KRAS) G12C. The company was incorporated in 2017 and is based in Shanghai, China. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2017
Country China
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2595
Full Company Profile

Financial Performance

In 2025, HKG:2595's revenue was 130.27 million, an increase of 24.42% compared to the previous year's 104.70 million. Losses were -1.79 billion, 164.8% more than in 2024.

Financial numbers in CNY Financial Statements

News

There is no news available yet.